Austco Healthcare is acquiring RTM for an estimated $15.26m, adding monitoring software used at 600+ Australian sites and expanding recurring revenue potential.

Medical Developments International’s Penthrox volumes rose 37% in Europe and 24% in Australian hospitals, despite quarterly revenue falling $700,000 to $10.2m.

Clever Culture Systems appoints PSC Biotech as sole sales agent for APAS Independence, targeting pharmaceutical makers in the US, Canada and Singapore.

PainChek expands Sabra US rollout to 23 care communities, securing 808 contracted memory care licences as it targets year-end activation.

Proteomics International independently validates PromarkerEndo, showing 90% sensitivity for stage IV endometriosis, with commercial availability targeted for FY27.

EBR Systems resets its US sales strategy after WiSE implants fell to 40 in the September quarter, as Medicare reimbursement rates rise by up to 93%.

Racura Oncology can escalate RC220 to 100mg/sqm in its lung cancer trial after no safety concerns emerged at the initial dose.

Clarity Pharmaceuticals hits SECuRE main-group recruitment target, advancing its prostate cancer therapy trial as Phase III planning gets underway.